PURPOSE: The purpose of this population analysis was to characterize the pharmacokinetic properties of robenacoxib in blood and stifle joint synovial fluid of dogs. METHODS: Data were obtained from two studies: 1) 8 healthy Beagle dogs in which an acute inflammation was induced by injection of urate crystals into one joint; 2) 95 dogs from various breeds diagnosed with osteoarthritis (OA). Robenacoxib concentrations in blood and synovial fluid were measured using a validated HPLC-UV and LC-MS method. Non-linear mixed effects modeling was performed using NONMEM6. RESULTS: A two-compartment pharmacokinetic model with linear elimination was developed to describe blood concentrations of robenacoxib. Blood clearance in healthy animals was found to be 75% higher than in OA dogs. Synovial fluid concentrations were modeled using an effect-compartment-type model predicting longer residence times in OA dogs compared to healthy Beagles (e.g. concentrations above the IC(50) for COX-2, respectively, 16 h vs. 10 h at 1.5 mg/kg). CONCLUSIONS: Robenacoxib was found to reside longer at the effect site (inflamed joint) compared to blood in both healthy and OA dogs. These results may explain the good efficacy observed with once-daily dosing in clinical trials and the high safety index of robenacoxib in dogs.
PURPOSE: The purpose of this population analysis was to characterize the pharmacokinetic properties of robenacoxib in blood and stifle joint synovial fluid of dogs. METHODS: Data were obtained from two studies: 1) 8 healthy Beagle dogs in which an acute inflammation was induced by injection of urate crystals into one joint; 2) 95 dogs from various breeds diagnosed with osteoarthritis (OA). Robenacoxib concentrations in blood and synovial fluid were measured using a validated HPLC-UV and LC-MS method. Non-linear mixed effects modeling was performed using NONMEM6. RESULTS: A two-compartment pharmacokinetic model with linear elimination was developed to describe blood concentrations of robenacoxib. Blood clearance in healthy animals was found to be 75% higher than in OA dogs. Synovial fluid concentrations were modeled using an effect-compartment-type model predicting longer residence times in OA dogs compared to healthy Beagles (e.g. concentrations above the IC(50) for COX-2, respectively, 16 h vs. 10 h at 1.5 mg/kg). CONCLUSIONS:Robenacoxib was found to reside longer at the effect site (inflamed joint) compared to blood in both healthy and OA dogs. These results may explain the good efficacy observed with once-daily dosing in clinical trials and the high safety index of robenacoxib in dogs.
Authors: J N King; J Dawson; R E Esser; R Fujimoto; E F Kimble; W Maniara; P J Marshall; L O'Byrne; E Quadros; P L Toutain; P Lees Journal: J Vet Pharmacol Ther Date: 2009-02 Impact factor: 1.786
Authors: Elisabeth C Jeunesse; Marc Schneider; Frederique Woehrle; Mathieu Faucher; Herve P Lefebvre; Pierre-Louis Toutain Journal: BMC Vet Res Date: 2013-12-11 Impact factor: 2.741
Authors: Marzia Stabile; Rossella Samarelli; Paolo Trerotoli; Laura Fracassi; Luca Lacitignola; Antonio Crovace; Francesco Staffieri Journal: Vet Sci Date: 2019-09-04
Authors: Peter Lees; Pierre-Louis Toutain; Jonathan Elliott; Jerome M Giraudel; Ludovic Pelligand; Jonathan N King Journal: J Vet Pharmacol Ther Date: 2022-04-22 Impact factor: 1.567
Authors: David Bennett; Peter David Eckersall; Mary Waterston; Veronica Marchetti; Alessandra Rota; Eilidh McCulloch; Silvia Sbrana Journal: BMC Vet Res Date: 2013-03-01 Impact factor: 2.741
Authors: Suresh B Lakshminarayana; Céline Freymond; Christoph Fischli; Jing Yu; Sebastian Weber; Anne Goh; Bryan K S Yeung; Paul C Ho; Véronique Dartois; Thierry T Diagana; Matthias Rottmann; Francesca Blasco Journal: Antimicrob Agents Chemother Date: 2014-12-08 Impact factor: 5.191